# A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

> **NCT06586957** · PHASE1 · RECRUITING · sponsor: **NiKang Therapeutics, Inc.** · enrollment: 150 (estimated)

## Conditions studied

- Solid Tumor
- Advanced Solid Tumor
- Solid Tumor, Adult
- Metastatic Tumor
- Ovarian Cancer
- Ovarian Neoplasms
- Ovarian Carcinoma
- Metastatic Ovarian Carcinoma
- Endometrial Neoplasms
- Endometrial Diseases
- Metastatic Endometrial Cancer
- Triple Negative Breast Cancer
- Metastatic Endometrial Carcinoma
- Advanced Endometrial Carcinoma
- Advanced Ovarian Carcinoma
- Gastric Cancer
- Advanced Gastric Carcinoma
- Metastatic Gastric Cancer
- Metastatic Gastric Carcinoma
- Small Cell Lung Cancer
- Small Cell Lung Carcinoma
- Triple Negative Breast Neoplasms
- Platinum-resistant Ovarian Cancer
- Platinum-refractory Ovarian Carcinoma
- CCNE1 Amplification
- Hormone Receptor Negative Breast Carcinoma
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Progesterone-receptor-positive Breast Cancer

## Interventions

- **DRUG:** NKT3964

## Key facts

- **NCT ID:** NCT06586957
- **Lead sponsor:** NiKang Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-19
- **Primary completion:** 2029-01
- **Final completion:** 2029-05
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06586957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06586957, "A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06586957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*